Sodium-Glucose Cotransporter-2 Inhibitors: Heart Failure and Renal Protection Indications

被引：2
|
作者：
El Hussein, Mohamed Toufic [1 ,2 ,3 ]
Bell, Nicole [4 ]
机构：
[1] Mt Royal Univ Calgary, Fac Hlth Community & Educ, Sch Nursing & Midwifery, Calgary, AB, Canada
[2] Univ Calgary Calgary, Fac Nursing, Calgary, AB, Canada
[3] Rockyview Gen Hosp Calgary, Coronary Care Unit, Med Cardiol, Calgary, AB, Canada
[4] Mt Royal Univ, Calgary, AB, Canada
来源：
JNP- THE JOURNAL FOR NURSE PRACTITIONERS | 2022年 / 18卷 / 02期
关键词：
heart failure; renal failure; sodium-glucose cotransporter-2 inhibitors; type; 2; diabetes; CARDIOVASCULAR EVENTS; EMPAGLIFLOZIN; RATIONALE; DESIGN; RISK;
D O I：
10.1016/j.nurpra.2021.09.002
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are a class of oral antihyperglycemic drugs recently added to clinical practice guidelines to manage type 2 diabetes mellitus (T2DM). Recent clinical trials have established significant benefits in using SGLT-2is to treat both heart failure and renal disease. This article aims to explain the clinical benefits of inhibiting sodium-glucose cotransporter-2 proteins in patients with T2DM, renal disease, and heart failure. These authors also seek to guide nurse practitioners in prescribing SGLT-2is. Evidence-based guidance for nurse practitioners to treat T2DM, heart failure, and renal disease is likely to improve patients' clinical outcomes and decrease associated morbidities. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码：179 / 184
页数：6
相关论文
共 50 条
  • [31] SODIUM-GLUCOSE COTRANSPORTER2 INHIBITORS IN HEART FAILURE
    Kazmierski, Wojciech
    Jurek, Jakub
    Lis, Paulina
    Lis, Anna
    Ziobro, Anna
    Ziomek, Mateusz
    Camlet, Katarzyna
    Kocur, Kinga
    PROSPECTS IN PHARMACEUTICAL SCIENCES, 2024, 22 (03): : 225 - 232
  • [32] Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
    Wei, Jiangjun
    Du, Jianlin
    CARDIOVASCULAR INNOVATIONS AND APPLICATIONS, 2023, 8 (01)
  • [33] Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?
    Pafili, K.
    Papanas, N.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (08) : 693 - 695
  • [34] Sodium-glucose cotransporter-2 inhibitors: where and when?
    Cowie, Martin R.
    FUTURE CARDIOLOGY, 2020, 17 (03) : 403 - 406
  • [35] RE: Gout and sodium-glucose cotransporter-2 inhibitors
    Lund, Lars Christian
    Hojlund, Mikkel
    Henriksen, Daniel Pilsgaard
    Hallas, Jesper
    Kristensen, Kasper Bruun
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 (01) : 114 - 115
  • [36] Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy
    Skrtic, Marko
    Cherney, David Z. I.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2015, 24 (01): : 96 - 103
  • [37] Premature Conclusion that Sodium-Glucose Cotransporter-2 Inhibitors Improve Kidney Outcomes in Patients with Heart Failure
    Zhang, Fan
    Zhang, Xianwen
    Zhong, Yifei
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025, 36 (02): : 325 - 326
  • [38] In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction
    Rao, Vishal N.
    Murray, Evan
    Butler, Javed
    Cooper, Lauren B.
    Cox, Zachary L.
    Fiuzat, Mona
    Green, Jennifer B.
    Lindenfeld, JoAnn
    McGuire, Darren K.
    Nassif, Michael E.
    Brien, Cara
    Pagidipati, Neha
    Sharma, Kavita
    Vaduganathan, Muthiah
    Vardeny, Orly
    Fonarow, Gregg C.
    Mentz, Robert J.
    Greene, Stephen J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (20) : 2004 - 2012
  • [39] Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials
    Kumar, Kris
    Kheiri, Babikir
    Simpson, Timothy F.
    Osman, Mohammed
    Rahmouni, Hind
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (11): : E625 - E630
  • [40] Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure
    Imprialos, Konstantinos
    Stavropoulos, Konstantinos
    Papademetriou, Vasilios
    HEART FAILURE CLINICS, 2019, 15 (04) : 519 - +
12345